The Pronutri's CEO talks about his experience with Strategic Challenge, Eurobiomed's new offering, which combines the expertise of its team and network to support members in their healthcare innovation projects.
How did the initial phase of needs assessment with Eurobiomed proceed?
Following promising advancements in our R&D project focused on reducing chemotherapy side effects, we needed to gain perspective. After several discussions with venture capitalists, we required a 360-degree audit to assess the potential valorization of our work.
Eurobiomed perfectly identified this challenge and proposed Strategic Challenge, an offering tailored to our development stage.
How did you perceive the complementarity of the experts mobilized for your support?
The support proved highly effective due to a flexible schedule, alternating between in-person and remote meetings, without being time-consuming.
The strength of the program lies in the selection of two complementary profiles: an expert in the therapeutic field of chemotherapy side effects, and a former startup CSO contributing expertise in scientific valorization. This duality provided us with both a technical and strategic perspective on our project.
What were the main contributions of the final deliverable to your company?
The report provided exceeded our expectations. Beyond analyzing the development stages, the experts conducted a detailed mapping of market players, existing forces, and key opinion leaders to engage.
They also presented various development scenarios, such as establishing a dedicated company or continuing in-house development, detailing the implications of each option. This comprehensive overview truly allowed us to gain a broader perspective on our project.
